The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2022

Filed:

Aug. 24, 2021
Applicant:

King Faisal University, Al-Ahsa, SA;

Inventors:

Mahmoud Kandeel Elsayed, Al-Ahsa, SA;

Mizuki Yamamoto, Kanagawa, JP;

Jin Gohda, Kanagawa, JP;

Jun-Ichiro Inoue, Tokyo, JP;

Yasushi Kawaguchi, Tokyo, JP;

Hyung-Joo Kwon, Cheongju, KR;

Abdulla Al-Taher, Al-Ahsa, SA;

Assignee:

KING FAISAL UNIVERSITY, Al-Ahsa, SA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/005 (2006.01); A61K 38/00 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); G01N 33/56983 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20033 (2013.01); G01N 2333/165 (2013.01); G01N 2496/00 (2013.01);
Abstract

Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.


Find Patent Forward Citations

Loading…